Targos offers highly standardised clinical biomarker services for the development of the international pharmaceutical and diagnostic industry
Based on its recent analysis of the in vitro diagnostics services market, Frost & Sullivan recognizes Targos Molecular Pathology GmbH with the 2011 European Frost & Sullivan Award for Customer Service Leadership. Targos is uniquely positioned to combine expertise in clinical and molecular pathology and highly standardised biomarker analysis with strict quality assurance.
Targos has superior time lines of service compared to its competitors, which have a turn-around-time (TAT) for not less than four days. Targos, on the other hand, has optimized the TAT for clinical tissue biomarker analysis to as low as 24 hours, enabling faster diagnostic test results and timely delivery of diagnostic services.
"The Targos team has proven its meticulousness, reliability and flexibility in handling small and very large projects to customers' satisfaction," said Frost & Sullivan Research Analyst Srinivas Sashidhar. "It provides a wide range of biomarker and other diagnostic services for histopathology, tissue analysis, expression profiling, enzyme-linked immunosorbent assay (ELISA) testing and related services including project, data and logistic management of biomarker studies."
Its services and expertise have appealed to customers, evidenced by the extension of long-term projects from 5 to 20 years. Targos’ proficiency in in vitro diagnostics services has also allowed it to expand its customer base to more than 30 top pharmaceutical, biotech and diagnostic companies.
Targos has a well-organized cost structure, which can be tailored according to the project or service. The costs include project management, logistics management and data management fees. Its diagnostic service costs are lesser than its competitors’.
"The company has been inspected by the Food and Drug Administration (FDA) and participates in College of American Pathologists (CAP) proficiency testing and lab improvement programmes," notes Sashidhar. "Targos, in collaboration with its pathology partners, has acted as Good Clinical Practice-compliant patho-diagnostic reference centre for more than 75 pharmaco-diagnostic trials."
Each year, Frost & Sullivan presents this award to the company that demonstrates excellence in customer service leadership within its industry. The recipient company shows tremendous responsiveness to customer needs and continually focuses on long and short-term customer profitability goals. In addition, it demonstrates flexibility in tailoring its product offerings to suit customer businesses.
Frost & Sullivan Best Practices awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis and extensive secondary research to identify best practices in the industry.
About Targos Molecular Pathology GmbH
Targos Molecular Pathology GmbH since 2005 has established itself as a preferred service provider for standardized analytics of clinical biomarkers. Targos central lab services allow its customers to perform global diagnostic and pharmaceutical approval trials under strict quality standards and lowest possible turn-around times for molecular pathology analyses. Targos thrives for steady improvement of service quality and portfolio and has currently 70 employees in three German sites.
About Frost & Sullivan
Frost & Sullivan (frost.com), the Growth Partnership Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best-practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages 50 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 40 offices on six continents.